Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study o...
Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
About this item
Full title
Author / Creator
Taylor, Matthew H. , Leboulleux, Sophie , Panaseykin, Yury , Konda, Bhavana , Fouchardiere, Christelle , Hughes, Brett G. M. , Gianoukakis, Andrew G. , Park, Young Joo , Romanov, Ilia , Krzyzanowska, Monika K. , Garbinsky, Diana , Sherif, Bintu , Pan, Jie Janice , Binder, Terri A. , Sauter, Nicholas , Xie, Ran and Brose, Marcia S.
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
In the phase 2 double‐blind Study 211, a starting dose of lenvatinib 18 mg/day was compared with the approved starting dose of 24 mg/day in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). Predefined criteria for noninferiority for efficacy in the 18 mg arm were not met; safety was similar in both arms. Imp...
Alternative Titles
Full title
Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_dc0ec1a8bab345c086c5e789e1eef9a5
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dc0ec1a8bab345c086c5e789e1eef9a5
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.5308
